文献速递免疫规划卫生政策与健康促进

阿根廷儿童20价肺炎球菌结合疫苗与低价次替代方案的成本效果分析

Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
PubMed 文献 · Vaccine · 2024-06-15

该研究采用决策分析马尔可夫模型,评估阿根廷国家免疫规划中儿童由PCV13转换为PCV15或PCV20的公共卫生与经济影响。结果显示,与PCV13和PCV15相比,PCV20可额外避免IPD、全因肺炎和全因中耳炎病例及死亡,并节省直接医疗成本,具有成本节约优势。

要点

  • 与PCV13相比,PCV20预计额外避免IPD 7,378例、全因肺炎42,884例、全因中耳炎172,389例及死亡3,308例。
  • 与PCV15相比,PCV20预计额外避免IPD 6,140例、肺炎35,258例、中耳炎142,366例及死亡2,624例。
  • PCV20较PCV13和PCV15均获得更高QALY且成本更低,即具优势地位。

核心结论

  • 在10年时间跨度内,阿根廷儿童接种PCV20预计较PCV13和PCV15为优势策略且节省成本。

研究设计与样本

  • 决策分析马尔可夫模型,时间跨度10年,成本和效益年贴现率3.0%,采用卫生系统视角。
  • 疫苗有效性估计来自阿根廷监测数据、PCV13临床有效性和影响研究及PCV7效力研究。
  • 人群、流行病学和经济学输入来自文献和阿根廷特定数据,并进行敏感性和情景分析。

主要发现

  • 与PCV13相比,PCV20预计额外避免IPD 7,378例、全因肺炎42,884例、全因中耳炎172,389例及死亡3,308例,节省直接医疗成本50,973,962美元。
  • 与PCV15相比,PCV20预计额外避免IPD 6,140例、肺炎35,258例、中耳炎142,366例及死亡2,624例,节省直接医疗成本37,697,868美元。
  • PCV20较PCV13和PCV15均获得更高的质量调整生命年增益和更低的成本,即具优势地位。
  • 敏感性和情景评估结果稳健。

临床怎么用

  • 作者建议 policymakers 应考虑PCV20接种策略,以较价次更低的选项实现最大临床和经济获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The 13-valent pneumococcal conjugate vaccine (PCV13) has been recommended for infants in Argentina's national immunization program (NIP) in a 2 + 1 schedule since 2012. Licensure of the 15-valent vaccine (PCV15) is anticipated soon, and the 20-valent vaccine (PCV20) recently received regulatory approval. This cost-effectiveness analysis examined the public health and economic implications of transitioning from PCV13 to either PCV15 or PCV20 in Argentina's pediatric NIP. METHODS: A decision-analytic Markov model was used with a 10-year time horizon and a 3.0% annual discount rate for costs and benefits. Vaccine effectiveness estimates were derived from Argentinian surveillance data, PCV13 clinical effectiveness and impact studies, and PCV7 efficacy studies. Population, epidemiologic, and economic inputs were obtained from literature and Argentinian-specific data. The study adopted a healthcare system perspective; sensitivity and scenario analyses were conducted to assess input parameters and structural uncertainty. RESULTS: Compared with PCV13, PCV20 was estimated to avert an additional 7,378, 42,884, and 172,389 cases of invasive pneumococcal disease (IPD), all-cause pneumonia, and all-cause otitis media (OM), respectively, as well as 3,308 deaths, resulting in savings of United States Dollars (USD) 50,973,962 in direct medical costs. Compared with PCV15, PCV20 was also estimated to have greater benefit, averting an additional 6,140, 35,258, and 142,366 cases of IPD, pneumonia, and OM, respectively, as well as 2,624 deaths, resulting in savings of USD 37,697,868 in direct medical costs. PCV20 was associated with a higher quality-adjusted life year gain and a lower cost (i.e., dominance) versus both PCV13 and PCV15. Results remained robust in sensitivity analyses and scenario assessments. CONCLUSION: Over a 10-year horizon, vaccination with PCV20 was expected to be the dominant, cost-saving strategy versus PCV13 and PCV15 in children in Argentina. Policymakers should consider the PCV20 vaccination strategy to achieve the greatest clinical and economic benefit compared with lower-valent options.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rey-Ares L, Ta A, Freigofaite D, et al. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina. Vaccine. 2024. PMID: 38879409. doi:10.1016/j.vaccine.2024.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。